CasInvent Pharma

General Information

Company Name

CasInvent Pharma

Founded Year

2020

Location (Offices)

Czech Republic +1

Founders / Decision Makers

Number of Employees

Industries

Pharmaceutical

Funding Stage

Seed

Social Media

CasInvent Pharma - Company Profile

CasInvent Pharma is a pharmaceutical startup with a mission to introduce innovative therapeutic options for selected leukemias to the market. The company's primary focus lies in the development of highly selective small molecule inhibitors of casein kinase I (CK1), with a key development program aimed at identifying new drugs for the treatment of acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). Established as a spin-off company of Masaryk University in cooperation with the investment partner i&i Prague in 2020, CasInvent Pharma is based in the Czech Republic. The company secured a significant €1.60M Seed Round investment on 31 January 2024 from a group of investors including i&I Bio, KHAN Technology Transfer Fund, i&i Prague, BIOINVESTIMED as, and the Holeček Family Foundation. CasInvent Pharma's slogan, "Novel Treatment of Leukemias, Lymphomas and Solid Tumors with Highly Potent and Selective Inhibitors of CK1 Kinases," encapsulates its commitment to pioneering treatment in the field of oncology.

Taxonomy: pharmaceuticals, leukemia treatment, oncology, small molecule inhibitors, drug development, investor partnership, Masaryk University, i&i Prague, spin-off company, CK1 kinase inhibitors, acute myeloid leukemia, chronic lymphocytic leukemia, proprietary drug development